CONTEXT: Prostate cancer (PCa) remains an increasingly common malignancy worldwide.
The optimal management of clinically localized, early-stage disease remains unknown, and …

Context The notion of insignificant prostate cancer (Ins-PCa) has progressively emerged in
the past two decades. The clinical relevance of such a definition was based on the fact that …

Background Prostate tumor heterogeneity and biopsy undersampling pose challenges to
accurate, individualized risk assessment for men with localized disease. Objective To …

Background Biomarkers that are validated in independent cohorts are needed to improve
risk assessment for prostate cancer (PCa). Objective A racially diverse cohort of men (20 …

Purpose We aimed to validate a previously described genetic risk score, denoted the cell-
cycle progression (CCP) score, in predicting contemporary radical prostatectomy (RP) …

Background Inherited DNA-repair gene mutations are more prevalent in men with advanced
prostate cancer than previously thought, but their clinical implications are not fully …

Widespread prostate-specific antigen (PSA)–based screening and aggressive treatment of
prostate cancer have reduced mortality rates substantially, but both remain controversial in …

Purpose Active surveillance (AS) is a treatment option for men with very low–risk prostate
cancer (PCa); however, favorable outcomes achieved for men in AS are based on cohorts …

Background Multiparametric magnetic resonance imaging (MP-MRI) may improve the
detection of clinically significant prostate cancer (PCa). Objective To compare MP-MRI …

Purpose Active surveillance (AS) is an option for the initial management of early-stage
prostate cancer. Current risk stratification schema identify patients with low-risk disease who …